The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. BridgeBio Pharma's Revenue for the
three
months ended in Mar. 2026 was €168.3 Mil. BridgeBio Pharma's average Accounts Receivable for the
three
months ended in Mar. 2026 was €148.3 Mil.
Hence, BridgeBio Pharma's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.13.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
BridgeBio Pharma Receivables Turnover Related Terms
BridgeBio Pharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for BridgeBio Pharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2CL vs EXEL, IONS, JAZZ: Receivables Turnover Comparison
For the Biotechnology subindustry, BridgeBio Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BridgeBio Pharma Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where BridgeBio Pharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Pharma (FRA:2CL) has a Receivables Turnover of 1.13 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BridgeBio Pharma and its competitors. According to the industry distribution chart, BridgeBio Pharma ranks #495 out of 840 companies in the Biotechnology industry, placing it in the top 58.9%.
Is BridgeBio Pharma's Receivables Turnover too high?
BridgeBio Pharma's current Receivables Turnover is 1.13. The Biotechnology industry median Receivables Turnover is 5.30. BridgeBio Pharma's value of 1.13 is 78.7% below this industry median. Based on the distribution chart, BridgeBio Pharma ranks #495 out of 840 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BridgeBio Pharma has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Pharma's Receivables Turnover compare to EXEL and IONS?
According to the Biotechnology industry distribution chart, BridgeBio Pharma ranks #495 out of 840 companies for Receivables Turnover. This places BridgeBio Pharma in the lower half of its industry. The industry median Receivables Turnover is 5.30. BridgeBio Pharma's value of 1.13 is 78.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.30, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BridgeBio Pharma's current Receivables Turnover of 1.13 is 78.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on BridgeBio Pharma and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BridgeBio Pharma's current Receivables Turnover is 1.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Pharma stock overvalued right now?
Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €126.29, compared to a current price of €76.60 — trading 39.3% below its estimated fair value. The current Receivables Turnover is 1.13 and 78.7% below the Biotechnology industry median of 5.30. BridgeBio Pharma's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current Receivables Turnover is 1.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?
Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued.
The current stock price of €76.60 is trading 39.3% below its estimated GF Value™ of €126.29.
GuruFocus considers BridgeBio Pharma to be Possible Value Trap.
Key valuation signals for FRA:2CL:
Receivables Turnover: 1.13
GF Value™: €126.29 vs. price of €76.60 (39.3% below fair value)
Industry Position: 78.7% below the Biotechnology median (#495 of 840)
No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
71GF Score
Get the complete analysis for FRA:2CL
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2CL has been successfully added to your 
